MMED Overview

MiniMed Group, Inc. is a global medical technology company that develops, manufactures, and markets a suite of solutions for the management of diabetes. The Company's fully integrated system addresses two key pain points for PWD: health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system, which consists of the components: the MiniMed 780G insulin pump, its second-generation insulin pump offering enhanced functionality and technological integration with other components of its 780G system; the Simplera Sync or Instinct CGM sensor, which are both easy-to-use, fully disposable, two-step insertion sensors; and its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings and adapts to ongoing changes in user behavior patterns every night. For PWD that choose to manage their diabetes with MDI instead of an insulin pump, it offers Smart MDI system.

Wall Street analysts forecast MMED stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMED is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MiniMed Group Inc revenue for the last quarter amounts to NaN USD, decreased

MiniMed Group Inc. EPS for the last quarter amounts to USD, decreased

MiniMed Group Inc (MMED) has 0 emplpoyees as of March 09 2026.

Today MMED has the market capitalization of 5.19B USD.